noscendo GmbH

About the Company

Rapid pathogen identification for sepsis & critical infections

Sepsis is a life-threatening organ dysfunction caused by an uncontrolled response to infection. Every hour of delayed appropriate antibiotic therapy increases mortality by 5–10%. Conventional culture-based pathogen identification takes 2–5 days — far too slow for critically ill patients.

noscendo's DISQVER® system uses next-generation sequencing (NGS) of circulating pathogen DNA from blood samples to deliver a comprehensive pathogen profile within hours — enabling targeted antibiotic therapy from the outset and dramatically improving patient outcomes.

The company was founded in 2016 and is headquartered in Germany. Dr. Peter Haug co-founded the company and served as CFO and Head of Business Development, contributing to two successful financing rounds and strategic partnerships with hospital networks.

Role of Dr. Peter Haug

✓ Co-Founder
✓ Chief Financial Officer (CFO)
✓ Head of Business Development
✓ Investor relations & fundraising
✓ Strategic partnerships

News & Press

noscendo in the press

Key milestones and coverage from across noscendo's development — from early grants through Series B financing.

Jul 2026

Acquisition

Bruker acquires DISQVER® platform from noscendo

Bruker Corporation (Nasdaq: BRKR) announced on 15 July 2026 the acquisition of the DISQVER® clinical metagenomics platform from noscendo GmbH. DISQVER® performs metagenomic next-generation sequencing (mNGS) of microbes directly from blood samples — detecting over 11,000 microbes and parasites in under 24 hours without prior cultivation. The acquisition extends Bruker's NGS-based infection detection capabilities and adds metagenomics applications to its portfolio for sepsis, bloodstream infections, and severe infectious diseases. Dr. Wolfgang Pusch, President of Bruker Microbiology & Infection Diagnostics: "DISQVER adds additional NGS applications to our portfolio for metagenomics and enhances our support for earlier decision-making in sepsis, bloodstream infections, and severe infections."

Bruker press release, 15 July 2026

May 2022

noscendo closes Series B financing round

noscendo GmbH successfully closed a Series B financing round to advance the DISQVER® next-generation sequencing platform for rapid pathogen identification in critically ill patients. The round enables further clinical validation studies and commercial scale-up.

noscendo press release, May 2022

Sept 2019

noscendo receives AWS start-up grant

The Austrian Federal Promotional Bank (AWS) selected noscendo for its prestigious start-up grant program, recognising the DISQVER® diagnostic system for sepsis as an innovative, high-impact medical technology. The grant supported further development and clinical studies.

AWS / noscendo press release, September 2019

May 2020

Sepsis diagnostics: noscendo featured in Ärztezeitung

Germany's leading medical newspaper Ärztezeitung reported on noscendo's approach to rapid sepsis diagnostics using next-generation sequencing, highlighting the clinical need for faster pathogen identification and noscendo's technology platform.

Ärztezeitung, May 2020

Mar 2021

IKK Südwest collaborates with noscendo

German health insurer IKK Südwest entered into a collaboration with noscendo to explore the integration of DISQVER®-based rapid pathogen diagnostics into clinical care pathways for sepsis patients, marking an important step toward routine clinical use.

IKK Südwest / noscendo, March 2021